These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients. Dalamaga M; Karmaniolas K; Matekovits A; Migdalis I; Papadavid E J Eur Acad Dermatol Venereol; 2008 May; 22(5):543-8. PubMed ID: 18070024 [TBL] [Abstract][Full Text] [Related]
7. Vasculitis and myelodysplasia. Belizna CC; Kerleau JM; Heron F; Cailleux N; Lévesque H Isr Med Assoc J; 2008 Feb; 10(2):156-7. PubMed ID: 18432035 [No Abstract] [Full Text] [Related]
8. [Immunologic phenomena as the first sign of myelodysplastic syndrome]. van Rijn RS; Wittebol S; Graafland AD; Kramer MH Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1529-33. PubMed ID: 11525083 [TBL] [Abstract][Full Text] [Related]
9. Prognosis of vasculitis associated myelodysplasia. Belizna C; Subra JF; Henrion D; Ghali A; Renier G; Royer M; Corre YL; Martin L; Voswinkel J; Ifrah N Autoimmun Rev; 2013 Aug; 12(10):943-6. PubMed ID: 23542504 [TBL] [Abstract][Full Text] [Related]
10. Leukocytoclastic vasculitis. A cutaneous expression of immune complex disease. Mackel SE; Jordon RE Arch Dermatol; 1982 May; 118(5):296-301. PubMed ID: 6211146 [TBL] [Abstract][Full Text] [Related]
11. Recurrence of abdominal large-vessel vasculitis and development of severe Sweet syndrome after a single cycle of 5-azacytidine in a patient with myelodysplastic syndrome. Kawano H; Suzuki T; Ishii S; Wakahashi K; Kawano Y; Sada A; Minagawa K; Ueno D; Yamasaki T; Itoh T; Yokozaki H; Katayama Y Eur J Haematol; 2014 Apr; 92(4):362-4. PubMed ID: 24341928 [No Abstract] [Full Text] [Related]
12. [Langerhans histiocytosis and acute monoblastic leukemia type LMA4]. Hermanns-Lê T; Arrese JE; Piérard GE Ann Dermatol Venereol; 1998 Feb; 125(2):124-6. PubMed ID: 9747230 [TBL] [Abstract][Full Text] [Related]